Cocrystal Pharma Files 8-K

Ticker: COCP · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1412486

Cocrystal Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyCocrystal Pharma, INC. (COCP)
Form Type8-K
Filed DateSep 12, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: CCPH

TL;DR

CCPH filed a routine 8-K, no major news.

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on September 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Cocrystal Pharma, Inc. is meeting its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for regulatory compliance and does not disclose any new material information or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing details.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is September 12, 2025.

In which U.S. state is Cocrystal Pharma, Inc. incorporated?

Cocrystal Pharma, Inc. is incorporated in Delaware.

What is the Commission File Number for Cocrystal Pharma, Inc.?

The Commission File Number for Cocrystal Pharma, Inc. is 001-38418.

What is the business address of Cocrystal Pharma, Inc.?

The business address of Cocrystal Pharma, Inc. is 19805 N. Creek Parkway, Bothell, WA 98011.

Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-12 17:30:19

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cocrystal Pharma, Inc. Date: September 12, 2025 By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing